Posted At PharmaLive

BY : Kevin Freking

The Prescription drug market for the treatment of Hypertension is to continue to rise in value from the $25 billion market that it already accounts for today. These are the findings from the latest visiongain report investigating this market area, "The World Hypertension Market 2005-2010".

The report also finds that of the pharmaceutical products which target this specific condition, six of these drugs have reached blockbuster status, generating in excess of $1 billion. However, the mass market potential has led to physicians being left with an increasingly difficult choice as to which is the most suitable course of treatment for the welfare of theirpatients.

"Hypertension is a major health problem in the world today, with the already large hypertensive population likely to increase over the next 10 years, especially due to ageing populations and the increasing prevalence of lifestyle factors conducive to hypertension and other cardiovascular problems," said report author, Dr Gordon Low.

The market is composed of five drug classes and the largest of those classes, in terms of revenue generation, is the angiotensin II blockers. This class generated $10.9bn in 2004, representing 43% of the entire market. This dominance is in spite of the fact that angiotensin II blockers are the newest class of drugs for Hypertension.

Hypertension is a worldwide epidemic, and is set to grow from approximately 1 billion sufferers in 2005, and that figure is set to grow by another 500 million by 2025.

This latest report from visiongain "The World Hypertension Market 2005-2010" analyses the market for the products that treat this condition, assesses the current market situation and forecasts where it is going over the medium-term.

Notes for editors:

To receive your complimentary overview of - The World Hypertension Market 2005-2010 - Please send an email to Sara Peerun sara.peerun@visiongain.com, telephone Sara on +44 (0) 20 8767 6711 or visit the media section on www.visiongainintelligence.com. Please include your full name, title of publication, contact telephone number, email, and details of where you saw this release. Upon receipt of this information, an overview will be emailed to you.

Background:

Visiongain is one of the fastest growing and most innovative independent media companies in Europe today. Based in London, UK, visiongain produce a host of business-2-business conferences, newsletters, management reports and E-Zines focusing on the Financial markets, the Pharmaceutical, Telecoms industries and the Defence sector.

For information on visiongain, please visit www.visiongain.com

Contact visiongain Sara Peerun, +44 (0)20 8767 6711 sara.peerun@visiongain.com